Hepatitis C-Viremic Kidneys Increasingly Used for Transplant
HCV-viremic kidneys are increasingly being used for transplants and seem to have good one-year outcomes.
Hepatitis C
FDA: Cases of Serious Liver Injury Reported With Certain HCV Agents
The FDA is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs.
Direct-Acting Antiviral Therapy Benefits Patients With HCV and HCC
Direct-acting antiviral therapy may be a beneficial therapy for patients infected with HCV with a history of hepatocellular carcinoma by increasing overall survival.
Kynurenine:Tryptophan Ratio Linked to Liver Fibrosis in Women With HIV, HCV
In people with HIV, the kynurenine/tryptophan (kyn/trp) ratio is elevated and is associated with greater liver fibrosis.
Guillain-Barre Syndrome Linked to Hepatitis C Virus Infection
The development of Guillain-Barre syndrome (GBS) has demonstrated an association with existing hepatitis C virus (HCV) infection and mixed cryoglobulinemia, according to a case study published in BMC Infectious Diseases. The subtype severe acute motor sensory axonal neuropathy was classified as a subtype of GBS through electromyography, associated with severe clinical presentation. Researchers noted that only…
Direct-Acting Antiviral Agents Safe for Hepatitis C
Direct-acting antiviral (DAA) exposure may not be associated with higher rates of any serious adverse events when used for hepatitis C virus (HCV) treatment, according to a study published in JAMA Network Open. At this time, there are approximately 2.4 million individuals living in the United States who are infected with HCV. Further, 28% of…
Lung and Heart Transplants From HCV-Infected Donors: Expert Roundtable
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Antiviral Therapy May Reduce Risk for Parkinson Disease in Chronic HCV
Investigators sought to determine the risk for Parkinson disease development in patients with hepatitis C virus who received antiviral treatment and in patients who did not receive this treatment.
Parkinson Disease Incidence Lower in Hep C Patients Who Receive Antivirals
Advantage of interferon-based antiviral therapy reached statistical significance at five-year follow-up
Glecaprevir/Pibrentasvir Approved to Treat All 6 Genotypes of HCV in Pediatric Patients
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
Next post in Hepatitis
